LPMX-1 is under clinical development by LipoMedix Pharmaceutical and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LPMX-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LPMX-1 overview
LPMX-1 (Promitil, PL-MLP) is under development for the treatment of solid tumors including metastatic colorectal cancer, ovarian cancer, breast cancer, melanoma, bladder cancer and pancreatic ductal adenocarcinoma (PDAC) which bears deleterious germline or somatic mutations in BRCA1, BRCA2, or HRD. The drug candidate is a new chemical entity prodrug of mitomycin-C administered through intravenous route. Mitomycin C is a methylazirino pyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. It targets DNA synthesis and function. The drug candidate is developed based on pegylated liposomal formulation technology.
It was also under development for the treatment of adenocarcinoma of the gastroesophageal junction, hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), gastric cancer, gallbladder cancer, rectal cancer, esophageal cancer, exocrine pancreatic cancer.
LipoMedix Pharmaceutical overview
LipoMedix Pharmaceutical (LipoMedix) operates as a developer of drugs for cancer therapy based on liposome delivery. The company’s product Promitil is a chemotherapeutic agent, which is used for treating cancer patients with solid tumors. It conducts clinical and pharmaceutical development of a patented prodrug of mitomycin-C (MMC) and its effective delivery in liposomes to cancer affected organs. The company’s pipeline portfolio offers Promitil (LPMX-1) which has completed Phase 1a study and targeted form of Promitil (LPMX-2) is in preclinical stage. It develops products to treat various types of cancers such as breast, stomach, colon, anal and bladder cancers. LipoMedix is headquartered in Jerusalem, Israel.
For a complete picture of LPMX-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
